Navigation Links
Alzheimer's Drug Shows Promise in Fighting Cancer

LOS ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers.

Q. Ping Dou, Ph.D., leader, Prevention Program at Karmanos, and members of his lab announced the findings of their study showing that the drug Clioquinol (CQ) appears to have an anti-tumor effect in mice bearing human prostate cancer cells. The announcement was made at the American Association of Cancer Research (AACR) annual meeting in Los Angeles, CA.

Dr. Dou and his team turned to the copper-binding compound CQ after discovering that prostate, breast, brain, colon and lung tumor tissue often have a higher level of copper than normal tissue. According to Dr. Dou, this led his team to investigate whether cancers with high levels of copper can lead to targeted treatment.

Karmanos researchers found that after binding CQ to the copper in prostate tumor tissue, the drug induces cell death in human prostate cancer cells.

According to Dr. Dou, his lab will take this information and work with Karmanos clinicians to create a treatment selectively targeting the copper found in tumors.

"We want to find out if we can target cancers that express high levels of copper," says Dr. Dou. "We hope to discover a compound that promotes tumor-killing activity."

The AACR was founded in 1907 by a group of eleven physicians and scientists interested in research, "to further the investigation and spread the knowledge of cancer." Today, AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and advocacy.

Based in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer. The Institute is one of 39 National Can cer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D. is the Institute's president and CEO.

Barbara Ann Karmanos Cancer Institute

CONTACT: Courtney McCrimmon, +1-412-225-6899, or Linda Remington,+1-313-576-8614, both of Barbara Ann Karmanos Cancer Institute

Web site: http://www.karmanos.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
7. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
8. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
9. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
10. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
11. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... 2017  Kratom leaves, from a South East ... used to prepare tea-like beverages and commercially manufactured ... annually to increase alertness, enhance well-being and occupational ... aches and pains. PinneyAssociates, review of the scientific ... FDA and DEA in determining the most appropriate ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Park ... financial planning services to families and business owners in the greater Kansas City ... children with developmental disabilities. , The Lakemary Center is a comprehensive educational resource ...
(Date:1/18/2017)... ... 18, 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), ... for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. ... through thought leader interaction in, live video and interactive digital platforms. , In ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse ... for a reset. The U.S. Apple Association agrees and recommends starting each day ... that contribute to heart disease. , The U.S. Apple Association – which represents apple ...
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has ... the Year. , Each year, Pink Elephant recognizes a new product or ... address a specific business problem or opportunity. The award highlights original innovations that were ...
Breaking Medicine News(10 mins):